About | Free Trial

Last Update

2016-06-09T00:00:00.000Z

This profile was last updated on . .

Is this you? Claim your profile.

Wrong Peter Mueller?

Dr. Peter Mueller R.

Chief Scientific Officer

Axcella Health Inc

HQ Phone: (857) 320-2200

Axcella Health Inc

840 Memorial Drive

Cambridge, Massachusetts 02139

United States

Company Description

We are pioneers in developing transformative medicines for patients with diseases in which disrupted amino acid biology plays a central role. We do this by identifying the amino acid profile associated with each disease and using our revolutionary technol... more

Find other employees at this company (1)

Background Information

Employment History

Society for Medicines Research

Executive Vice President of Global Research and Development and Chief Scientific Officer
Vertex Pharmaceuticals Incorporated

Senior Vice President for Research and Development
Boehringer Ingelheim Corporation

President of Research and Development and CSO
Pronutria Inc

President
Epicenter Consulting LLC

Chief Operating Officer
Amarillo Biosciences , Inc.

Vice President of Global Marketing
Aventis SA

Vice President, Global Marketing Business and Marketing Services
Hoechst Marion Roussel , Inc.

Director of Global Commercial Development
Merrell Dow

Affiliations

Member
Gesellschaft Deutscher Chemiker

Board Member
Inhibikase Therapeutics Inc

Advisory Board Member
USA India Chamber of commerce

Advisory Board Member
Phacilitate Limited

Scientific Advisory Board Member
Keystone Symposia

Advisory Board Member
Biosensor Forum

Delegate
GDS International Ltd

Faculty Member
Albert Einstein University of Ulm , Germany

Member
American Association for the Advancement of Science

Member
Royal Society of Chemistry

Member
The RNA Society

Member of Council On Economic Competitiveness and Technology for the State of Connecticut
Govenor Roland

Education

MBA

Babson

Ph.D.
Pharmacology
University of Mainz

Ph.D. degree
pharmaceuticals
University of Mainz , Germany

PhD
Chemistry
Albert Einstein University of Ulm , Germany

undergraduate degree

Albert Einstein University of Ulm , Germany

Web References (166 Total References)


Peter Mueller, ...

www.axcellahealth.com [cached]

Peter Mueller, PhD Chief Scientific Officer


Peter Mueller, ...

www.axcellahealth.com [cached]

Peter Mueller, PhD

Chief Scientific Officer
Prior to his time at Axcella, Dr. Peter Mueller was the Executive Vice President of Global Research and Development & Chief Scientific Officer at Vertex Pharmaceuticals. At Vertex, he provided strategic oversight for Vertex's worldwide drug discovery and development programs. He was responsible for the build out, lead and advance integrated Research in North America, Europe and China, Pharmaceutical Development, Quality Assurance and Control, Pharmaceutical Operations and Supply Chain, as well as Clinical and Non-Clinical Development, Regulatory and Medical Affairs and Patient Safety. Key areas of Vertex's R&D have been hepatitis C (HepC), cystic fibrosis (CF), Immune Mediated Intestinal Diseases (IMID), cancer and neurological diseases. His leadership led to the successful approval and launch of two breakthrough drugs, INCIVEK (HepC) in 2011, and KALYDECO (CF) in 2012, as well as a, NDA and MAA for Orkambi (CF) and numerous sNDA submissions for KALYDECO (CF) and several proof of clinical concept candidates in various disease areas (Flu, HepC, Cancer, CF, RA). Both Breakthrough Therapies got awarded the prestigious Prix Galien award (U.S., Telaprevir) and its European counterpart the Galenus Preis (Kalydeco). Prior to his time at Vertex, Dr. Mueller served as Senior Vice President, Research and Development, for Boehringer Ingelheim Pharmaceuticals, Inc., where he was responsible for research in North America and the development of all drug candidates of the company's worldwide portfolio in North and South America, Canada and Japan, beginning in 1997. He played a key role in the development of Spiriva, Combivent and Atrovent. He also led research programs in the areas of immunology, inflammation, cardiovascular disease and gene therapy on a global basis. During his time with Boehringer Ingelheim (BI), starting there in 1984, Dr. Mueller oversaw the discovery of numerous development candidates, held several positions in basic research, medicinal chemistry and management in different centers of BI worldwide.
Dr. Mueller received both an undergraduate degree and a Ph.D. in chemistry at the Albert Einstein University of Ulm, Germany, where he also holds a Professorship in Theoretical Organic Chemistry. He completed fellowships in Quantum Pharmacology at Oxford University and in Biophysics at Rochester University. Special Fields of studies are Synthetic Organic Chemistry, Computational Chemistry (Cheminformatics and Bioinformatics), RNA-Biophysics, Atherosclerosis Research, IMID (Immune Mediated Inflammatory Diseases), Neurodegenerative Diseases, Infection, Oncology, Gene/ Epigenetic Technology and Management Strategies. He is a Board member of various scientific and political societies, such as the Gesellschaft Deutscher Chemiker (GDCh) and Verband Chemische Industrie (Germany), Royal Society of Chemistry (U.K.); U.S.-India Chamber of Commerce Biotech, Pharma & Medical Devices Council, IRI, RNA-Society, ASAP, AAAS (USA), Inhibikase, Visterra and Kaleido. He has also supported the Harvard Accelerator Fund, the Scientific Advisory Board for Keystone Conferences, and the Governor Roland's Council on Economic Competitiveness and Technology for the State of Connecticut (USA).


CF Worldwide Blog ยป Treatment with VX-661 and Ivacaftor in a Phase 2 Study Resulted in Statistically Significant Improvements in Lung Function in People with Cystic Fibrosis Who Have Two Copies of the F508del Mutation

www.cfww.org [cached]

"This first study of VX-661 and ivacaftor provides further validation of the strategy of combining a corrector and potentiator to improve lung function in people with the most common type of cystic fibrosis,"Peter Mueller, Ph.D., Chief Scientific Officer and Executive Vice President of Global Researchand Development at Vertex.


Board of Directors | Inhibikase Therapeutics, Inc.

www.inhibikase.com [cached]

Peter Mueller, PhD.

Dr. Mueller joined Vertex in July 2003. As Executive Vice President Global Research and Development & Chief Scientific Officer, he provides strategic oversight for Vertex's worldwide drug discovery research programs, Pharmaceutical Development, Quality Assurance and Control, Pharmaceutical Operations as well as Clinical and Non-Clinical Development, Regulatory, Patient Safety and Medical Affairs. Key areas of Vertex' R&D are Hepatitis C, Cystic Fibrosis, IMID, Cancer, and Neurological Diseases which led in 2011 to the successful approval and launch of INCIVEK (HepC), a NDA/MAA submission for KALYDECO (CF) with the first approval in the US in January 2012 and several proof of clinical concept candidates in various disease areas. Prior to coming to Vertex, Dr. Mueller served as Senior Vice President, Research and Development, for Boehringer Ingelheim Pharmaceuticals, Inc. where he was responsible for the development of all drug candidates of the company's worldwide portfolio in North and South America, Canada and Japan, beginning in 1997. He also led research programs in the areas of immunology, inflammation, cardiovascular disease and gene therapy on a global basis. During his time with Boehringer Ingelheim, Dr. Mueller oversaw the discovery of numerous development candidates, held several positions in basic research, medicinal chemistry and management in different centers of BI worldwide.
Dr. Mueller received both an undergraduate degree and a Ph.D. in Chemistry at the Albert Einstein University of Ulm, Germany, where he also holds a Professorship in Theoretical Organic Chemistry. He completed fellowships in Quantum Pharmacology at Oxford University and in Biophysics at Rochester University.


USA India Chamber of commerce - Delivering Affordable Innovation through Global Partnerships

www.usaindiachamber.org [cached]

Dr. Peter Mueller President R&D and CSO Pronutria Biosciences

Similar Profiles

Other People with this Name

Other people with the name Mueller

Chris Mueller
F & M Bank

Zach Mueller
Medical City Hospital

Karin Mueller
London Vet Show

nChris Mueller
F&M Bank

Matthias Mueller
Volkswagen AG

Browse ZoomInfo's Business Contact Directory by City

Browse ZoomInfo's
Business People Directory

Browse ZoomInfo's
Advanced Company Directory